Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclokat phase III trial in severe dry eye disease
2011-000160-97Phase 3Completed
- Sponsor
- Novagali Pharma
- Start
- Mar 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing Cyclokat with Vehicle control (2 arms). Primary endpoint: Improvement from baseline in corneal fluorescein staining score. Started Mar 2011; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2011-000160-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000160-97.